Skip to main content

Clinical Trials Using Exemestane

Review the clinical trials studying exemestane on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 26

Testing the Usual Treatment of Radiation Therapy and Hormonal Therapy to Hormonal Therapy alone for Low-Risk, Early Stage Breast Cancer, the DEBRA Trial
Status: Active
Location: 753 locations
Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam Trial
Status: Active
Location: 707 locations
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Status: Active
Location: 53 locations
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Status: Active
Location: 42 locations
Hormonal Therapy after Pertuzumab and Trastuzumab for the Treatment of Hormone Receptor Positive, HER2 Positive Breast Cancer, the ADEPT study
Status: Active
Location: 42 locations
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
Status: Active
Location: 32 locations
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
Status: Active
Location: 24 locations
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Status: Active
Location: 23 locations
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
Status: Active
Location: 18 locations
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
Status: Active
Location: 14 locations
Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
Status: Active
Location: 15 locations
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Status: Active
Location: 12 locations
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Status: Active
Location: 14 locations
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Status: Active
Location: 10 locations
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
Status: Active
Location: 13 locations
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Status: Active
Location: 7 locations
Abemaciclib in Combination with Endocrine Therapy for the Treatment of Older Patients with Hormone Receptor Positive Metastatic Breast Cancer
Status: Active
Location: 6 locations
Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
Status: Active
Location: 5 locations
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Status: Active
Location: 3 locations
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
Status: Active
Location: 3 locations
Medication Switch versus Guideline-directed Intervention (Side Effect Management) in Reducing Side Effects of Aromatase Inhibitors in Estrogen Receptor Positive HER2 Negative Breast Ductal Carcinoma In Situ and Stage I-III Invasive Breast Cancer, SWIVEL Trial
Status: Active
Location: Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon, New Hampshire
A Vaccine (MUC1 Peptide-Poly-ICLC) for the Treatment of Estrogen Receptor Positive Breast Ductal Carcinoma in Situ
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Avasopasem for the Treatment of Patients with Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer with Progression on a CDK4/6 Inhibitor and Hormonal Therapy
Status: Active
Location: Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
Status: Active
Location: Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas
Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
Status: Enrolling by Invitation
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington